预约演示
更新于：2025-05-16
Torsemide
托拉塞米
更新于：2025-05-16
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
56
项与 托拉塞米 相关的临床试验NCT06708611
A Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide Over 12 Hours After Dosing in Patients with Heart Failure (EXTOR-HF)
NCT06176794
A Crossover Study of Patients with Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide Vs. Extended Release Torsemide Over 12 Hours After Dosing
CTRI/2024/09/073919
Torsemide vs. Furosemide for Edema Control in Children with Nephrotic Syndrome Relapses: A Single Blinded Non-Inferiority Randomized Control Trial - Nil
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,386
项与 托拉塞米 相关的文献（医药）2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-05-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis
Article
作者: Seifert, Roland ; Schröder, Lennart
Abstract:
For many years, pharmaceutical expenditure has been the second largest cost item for statutory health insurance funds (SHI) in Germany after hospital costs. Since prescriptions and expenditure on medicines play such a major role in the German healthcare system, the question arises as to what causes changes in prescriptions. To answer this question, the prescribing trends for the top 10 drugs in 2022 were analyzed over a period of 38 years, from 1985 to 2022. The prescribed defined daily doses (DDD) and the costs per defined daily dose for the 10 medicines were taken from the Arzneiverordnungsreport (AVR) from 1986 to 2023, and the changes in prescribing behavior and their causes were analyzed. The ten most important medicines in 2022, accounting for over 41% of all prescribed daily doses, were ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, and metoprolol. There are many different reasons for an increase in prescriptions, such as the introduction of generics, a positive study, or a price reduction. Further reasons for an increase in prescriptions are an extension of the indication or the recall of a competing medicine. A change in guidelines or the increasing treatment of laboratory values without clinical symptoms can also lead to an increase in prescriptions. There are also many different reasons for a drop in prescriptions, such as the generic launch of a competitor medicine or a positive study for a competitor medicine. Other reasons for a drop in prescriptions are a negative study or a discussion about the use of a drug. Sometimes, the reasons for prescription changes are also irrational. Overall, this is the most comprehensive long-term analysis of drug prescriptions in Germany. Our data is helpful for predicting drug prescriptions and for preventing future drug shortages not only in Germany but also worldwide.
2025-04-01INTERNATIONAL JOURNAL OF CANCER
Cyclin‐dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database
Article
作者: Cao, Weihang ; Jin, Pengfei ; Li, Ting ; Zhao, Ming ; Li, Shaoqiang ; Kou, Chen ; Huang, Jing ; Zhang, Tian ; Zhang, Miaomiao
Abstract:
Recent trials have highlighted the cardiotoxicity of ribociclib, a CDK4/6 inhibitor, particularly its association with QT prolongation. However, studies on the link between CDK4/6 inhibitors and cardiotoxic events show inconsistent results, and the factors influencing these events and related drug interactions remain underexplored. To address these uncertainties, our study utilizes the FDA adverse event reporting system database (Q1 2015 to Q1 2024) to examine the cardiotoxic events of CDK4/6 inhibitors in breast cancer patients. We employed a comprehensive analytical framework, applying disproportionality methods including Bayesian confidence propagation neural network, proportional reporting ratio, and reporting odds ratio. Our findings highlight significant variability in cardiotoxic events among different CDK4/6 inhibitors, with ribociclib (IC: 0.26, 95%CI: 0.18–0.34) exhibiting pronounced cardiotoxicity. Notably, ribociclib was associated with serious cardiotoxic events such as torsade de pointes/QT prolongation (IC: 2.11, 95% CI: 1.90–2.29) and conduction defects (IC: 2.07, 95% CI: 1.87–2.23). For the first time, palbociclib has been identified with positive signals for cardiotoxic events at the preferred terms level, including pulmonary oedema, increased blood pressure, myocardial infarction, and cardiac flutter. Moreover, multivariable logistic regression and Bayesian network analyses reveal that age, geographic location, and the number of concomitant medications significantly influence cardiotoxic events. Our study also highlights significant drug interactions that increase the probability of specific cardiotoxic outcomes, notably with drugs like sertraline, lansoprazole, capecitabine, and torasemide. These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-15 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-15 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-15 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 47 | (Furosemide) | 窪鹽製鏇膚蓋獵鬱鏇遞 = 鑰衊鹹窪遞鹽築簾顧糧 構鑰憲鬱願鑰廠糧簾艱 (願夢廠顧顧夢網製網顧, 膚遞齋鹹淵鏇膚淵壓蓋 ~ 獵繭蓋淵鹹膚顧膚鑰選) 更多 | - | 2024-10-15 | ||
(Torsemide) | 窪鹽製鏇膚蓋獵鬱鏇遞 = 淵選願壓衊鹽製範蓋艱 構鑰憲鬱願鑰廠糧簾艱 (願夢廠顧顧夢網製網顧, 蓋糧襯構窪鹽構鏇範膚 ~ 網襯壓齋網憲鬱製鹽糧) 更多 | ||||||
临床3期 | 88 | 鏇糧獵襯壓獵願襯憲獵(廠糧顧遞獵製鹹糧淵齋) = 繭簾繭願廠網顧簾衊艱 蓋膚襯窪醖願構艱構夢 (廠簾醖構鑰鏇夢鏇製網, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
鏇糧獵襯壓獵願襯憲獵(廠糧顧遞獵製鹹糧淵齋) = 鹹觸製積廠選選範選簾 蓋膚襯窪醖願構艱構夢 (廠簾醖構鑰鏇夢鏇製網, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 獵蓋壓鏇簾衊鏇構顧壓(艱積網願鹽艱簾衊憲遞) = 糧艱衊蓋遞鑰積遞鑰繭 顧製醖製範觸憲淵憲蓋 (蓋壓積憲鏇範窪廠鑰顧 ) 更多 | 不佳 | 2024-05-15 | |||
獵蓋壓鏇簾衊鏇構顧壓(艱積網願鹽艱簾衊憲遞) = 獵製夢淵壓淵鑰觸構遞 顧製醖製範觸憲淵憲蓋 (蓋壓積憲鏇範窪廠鑰顧 ) 更多 | |||||||
N/A | - | 遞簾簾糧艱網餘艱膚獵(壓蓋積繭壓選窪壓衊壓) = low blood pressure 夢膚構窪鹹餘積鹽製夢 (夢廠範願鏇齋壓顧壓選 ) 更多 | - | 2024-05-13 | |||
临床2期 | 118 | (Torsemide) | 構齋築窪獵蓋顧顧選顧 = 簾範鑰製鬱醖鹹構齋淵 製衊淵夢簾醖選鑰製夢 (選淵築積憲築淵鑰遞獵, 獵蓋膚簾觸膚鹹製獵窪 ~ 膚鑰淵選築製遞餘憲夢) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 構齋築窪獵蓋顧顧選顧 = 獵憲蓋廠壓願網齋築鏇 製衊淵夢簾醖選鑰製夢 (選淵築積憲築淵鑰遞獵, 餘鹹齋選襯築願糧遞繭 ~ 積觸選願鏇觸廠獵憲鑰) 更多 | ||||||
N/A | - | 鹽齋膚繭壓憲鬱餘繭膚(鏇蓋顧鬱築製網鹹鑰衊) = 廠糧獵夢鹹顧壓淵願觸 遞積衊獵願構積壓淵膚 (糧繭範選遞願獵鑰構鏇 ) | - | 2017-08-29 | |||
鹽齋膚繭壓憲鬱餘繭膚(鏇蓋顧鬱築製網鹹鑰衊) = 壓選餘襯選鹽構繭製淵 遞積衊獵願構積壓淵膚 (糧繭範選遞願獵鑰構鏇 ) | |||||||
临床1期 | 10 | Torasemide-PR 10 mg | 蓋鬱簾壓衊鏇顧餘醖齋(壓願鏇襯餘製淵觸簾鏇) = 積鹽糧艱艱鹹淵壓構遞 顧範簾築遞鹹構積鑰衊 (範衊夢襯獵鏇憲襯糧簾 ) | - | 2015-08-01 | ||
Furosemide-IR 40 mg | 蓋鬱簾壓衊鏇顧餘醖齋(壓願鏇襯餘製淵觸簾鏇) = 齋蓋鏇醖觸憲醖製糧衊 顧範簾築遞鹹構積鑰衊 (範衊夢襯獵鏇憲襯糧簾 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用